Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

High-resolution molecular imaging of cardiac fibrosis with a novel collagen-specific MRI contrast agent

EF 2025-26

Résumé
Heart disease is the leading cause of death worldwide, and one of the main drivers of heart failure is fibrosis - the buildup of scar tissue that stiffens the heart and limits its ability to pump blood. After a heart attack, the body repairs itself by producing collagen, the structural protein that forms scar tissue. While some scarring is necessary for healing, excessive or misplaced fibrosis leads to poor recovery and increases the risk of heart failure. A critical problem is that fibrosis cannot currently be monitored as it develops. Existing imaging methods only show the scar after it has already matured, long after the processes that determine whether a patient recovers well or poorly have taken place. This gap leaves us unable to detect disease early, understand how it evolves, or measure whether promising new anti-fibrotic therapies are working. I hypothesize that a collagen-targeted MRI contrast agent, Mn-ScarTrac, can fill this gap by tracking fibrosis in the heart with molecular precision and sensitivity in a preclinical heart attack model. To achieve this, I will establish the safety of Mn-ScarTrac in animals and confirm its ability to bind to human scar tissue samples. Next, I will apply Mn-ScarTrac in a preclinical model of heart attack, imaging the heart at multiple time points to capture how scar tissue forms, spreads, and contributes to deteriorated heart function. I will also compare fibrosis in hearts with and without high blood pressure, since this common risk factor changes how the heart remodels after injury. Finally, I will test whether Mn-ScarTrac can detect resolution of fibrosis when animals are treated with an anti-fibrotic drug, providing a way to monitor therapy in real time. This project aims to establish a powerful imaging tool that reveals how fibrosis unfolds in different disease settings and will advance the development of personalized therapies to prevent heart failure.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559676
Name
Liu Kaiwen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
High-resolution molecular imaging of cardiac fibrosis with a novel collagen-specific MRI contrast agent
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Anti-Fibrotic Therapeutics; Cardiac Fibrosis; Cardiovascular System; Collagen Targeted Imaging; Heart Failure Pathophysiology; In Vivo Mouse Model; Magnetic Resonance Imaging; Molecular Mri Contrast Agents; Myocardial Infarction; Personalized Cardiovascular Medicine
Abstract
Heart disease is the leading cause of death worldwide, and one of the main drivers of heart failure is fibrosis - the buildup of scar tissue that stiffens the heart and limits its ability to pump blood. After a heart attack, the body repairs itself by producing collagen, the structural protein that forms scar tissue. While some scarring is necessary for healing, excessive or misplaced fibrosis leads to poor recovery and increases the risk of heart failure. A critical problem is that fibrosis cannot currently be monitored as it develops. Existing imaging methods only show the scar after it has already matured, long after the processes that determine whether a patient recovers well or poorly have taken place. This gap leaves us unable to detect disease early, understand how it evolves, or measure whether promising new anti-fibrotic therapies are working. I hypothesize that a collagen-targeted MRI contrast agent, Mn-ScarTrac, can fill this gap by tracking fibrosis in the heart with molecular precision and sensitivity in a preclinical heart attack model. To achieve this, I will establish the safety of Mn-ScarTrac in animals and confirm its ability to bind to human scar tissue samples. Next, I will apply Mn-ScarTrac in a preclinical model of heart attack, imaging the heart at multiple time points to capture how scar tissue forms, spreads, and contributes to deteriorated heart function. I will also compare fibrosis in hearts with and without high blood pressure, since this common risk factor changes how the heart remodels after injury. Finally, I will test whether Mn-ScarTrac can detect resolution of fibrosis when animals are treated with an anti-fibrotic drug, providing a way to monitor therapy in real time. This project aims to establish a powerful imaging tool that reveals how fibrosis unfolds in different disease settings and will advance the development of personalized therapies to prevent heart failure.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Liu, Kaiwen
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~